Weakness in Merrimack Pharmaceuticals (NASDAQ: MACK) following FDA approval of ONIVYDE presents a buying opportunity, according to Eric Criscuolo of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA

Merrimack Pharmaceuticals (MACK) PT Raised to $15 at OppenheimerOctober 27, 2015 8:17 AM Merrimack (MACK) Onivyde Labeling Appears as Expected, Says Mizuho SecuritiesOctober 22, 2015 2:14 PM Merrimack Pharma (MACK) Drops Lower Following ONIVYDE Approval; Will Include 'Boxed Warning'October 22, 2015 2:10 PM Merrimack Pharma (MACK) to Resume Trading at 1:40 PM EDTOctober 22, 2015 1:32 PM Merrimack Announces U.S. FDA Approval of ONIVYDE™ (irinotecan liposome injection) for the Treatment of Patients with Metastatic Pancreatic CancerOctober 22, 2015 1:11 PM Streetinsider.com's Hot Lunchtime Reads 10/22: (LL) (AAPL) (MACK) (BABA)October 22, 2015 12:22 PM FDA Approves Merrimack Pharma's (MACK) ONIVYDEOctober 22, 2015 11:32 AM